Sifei Xing

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11365970/publications.pdf

Version: 2024-02-01

| | | 1163117 | 1588992 | |
|----------|----------------|--------------|----------------|--|
| 8 | 1,326 | 8 | 8 | |
| papers | citations | h-index | g-index | |
| | | | | |
| | | | | |
| 8 | 8 | 8 | 1787 | |
| all docs | docs citations | times ranked | citing authors | |
| | | | | |

| # | Article | IF | CITATIONS |
|---|---|------|-----------|
| 1 | An In-Depth Comparison of Latent HIV-1 Reactivation in Multiple Cell Model Systems and Resting CD4+ T Cells from Aviremic Patients. PLoS Pathogens, 2013, 9, e1003834. | 4.7 | 360 |
| 2 | Small-molecule screening using a human primary cell model of HIV latency identifies compounds that reverse latency without cellular activation. Journal of Clinical Investigation, 2009, 119, 3473-86. | 8.2 | 224 |
| 3 | BET bromodomain-targeting compounds reactivate HIV from latency via a Tat-independent mechanism. Cell Cycle, 2013, 12, 452-462. | 2.6 | 209 |
| 4 | Disulfiram Reactivates Latent HIV-1 in a Bcl-2-Transduced Primary CD4 ⁺ T Cell Model without Inducing Global T Cell Activation. Journal of Virology, 2011, 85, 6060-6064. | 3.4 | 174 |
| 5 | Transcriptional Reprogramming during Effector-to-Memory Transition Renders CD4+ T Cells Permissive for Latent HIV-1 Infection. Immunity, 2017, 47, 766-775.e3. | 14.3 | 160 |
| 6 | Targeting HIV latency: pharmacologic strategies toward eradication. Drug Discovery Today, 2013, 18, 541-551. | 6.4 | 131 |
| 7 | Novel structurally related compounds reactivate latent HIV-1 in a bcl-2-transduced primary CD4+ T cell model without inducing global T cell activation. Journal of Antimicrobial Chemotherapy, 2012, 67, 398-403. | 3.0 | 39 |
| 8 | Unique characteristics of histone deacetylase inhibitors in reactivation of latent HIV-1 in Bcl-2-transduced primary resting CD4+ T cells. Journal of Antimicrobial Chemotherapy, 2014, 69, 28-33. | 3.0 | 29 |